distal arthrogryposis type 2B1

Summary

distal arthrogryposis type 2B1 (MONDO:0020820) is a disease caused by variants in MYH3, TNNI2, and TNNT3, with 4 cohort genes. The dominant Reactome pathway is Striated Muscle Contraction (4 cohort genes).

At a glance

• Causal genes: MYH3 (GenCC Strong), TNNI2 (GenCC Strong), TNNT3 (GenCC Strong)
• Cohort genes: 4
• ClinVar variants: 209

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	distal arthrogryposis type 2B1
Mondo ID	MONDO:0020820
OMIM	601680
DOID	DOID:0111600
UMLS	C5193014
MedGen	1676961
GARD	0009909
Is cancer (heuristic)	no

Also known as: arthrogryposis, distal, type 2B1 · DA2B1

Data availability: 209 ClinVar variants · 5 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal dominant disease › distal arthrogryposis type 2B1

Related subtypes (191): autosomal dominant polycystic liver disease, cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1, tuberous sclerosis, Treacher-Collins syndrome, hereditary breast ovarian cancer syndrome, autosomal dominant polycystic kidney disease, Lynch syndrome, branchio-oto-renal syndrome, autosomal dominant Aarskog syndrome, acroosteolysis dominant type, ADULT syndrome, autosomal dominant Alport syndrome, amelogenesis imperfecta type 1B, Townes-Brocks syndrome, nevoid basal cell carcinoma syndrome, blepharophimosis, ptosis, and epicanthus inversus syndrome, autosomal dominant brachyolmia, branchiooculofacial syndrome, pheochromocytoma/paraganglioma syndrome 4, cataract-aberrant oral frenula-growth delay syndrome, cherubism, autosomal dominant chondrodysplasia punctata, autosomal dominant popliteal pterygium syndrome, blepharocheilodontic syndrome, cochleosaccular degeneration-cataract syndrome, renal coloboma syndrome, Beare-Stevenson cutis gyrata syndrome, autosomal dominant vibratory urticaria, neurohypophyseal diabetes insipidus, autosomal dominant Kenny-Caffey syndrome, Rapp-Hodgkin syndrome, Ehlers-Danlos syndrome, classic type, autosomal dominant Ehlers-Danlos syndrome, vascular type, multiple endocrine neoplasia type 1, Coffin-Siris syndrome 1, isolated congenital adermatoglyphia, Flynn-Aird syndrome, Frasier syndrome, hand-foot-genital syndrome, Holt-Oram syndrome, hyperkeratosis-hyperpigmentation syndrome, autosomal dominant ichthyosis vulgaris, hyper-IgE recurrent infection syndrome 1, autosomal dominant, autosomal dominant keratitis, autosomal dominant keratitis-ichthyosis-hearing loss syndrome, LADD syndrome, trichorhinophalangeal syndrome type II, Noonan syndrome with multiple lentigines, microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability, Marfan syndrome, melanoma, cutaneous malignant, susceptibility to, 2, autosomal dominant primary microcephaly, autosomal dominant progressive external ophthalmoplegia, monilethrix, Muir-Torre syndrome, autosomal dominant myoglobinuria, autosomal dominant centronuclear myopathy, nail-patella syndrome, multiple endocrine neoplasia type 2B, autosomal dominant omodysplasia, pheochromocytoma/paraganglioma syndrome 1, Pelger-Huet anomaly, multiple endocrine neoplasia type 2A, piebaldism, autosomal dominant medullary cystic kidney disease with or without hyperuricemia, generalized juvenile polyposis/juvenile polyposis coli, juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, Peutz-Jeghers syndrome, contractures, pterygia, and spondylocarpotarsal fusion syndrome 1A, autosomal dominant distal renal tubular acidosis, retinoschisis, autosomal dominant, autosomal dominant Robinow syndrome, scapuloperoneal spinal muscular atrophy, autosomal dominant, autosomal dominant sideroblastic anemia, spondyloepiphyseal dysplasia tarda, autosomal dominant, proximal symphalangism, calcaneonavicular coalition, thanatophoric dysplasia type 1, trichorhinophalangeal syndrome type I, Muckle-Wells syndrome, autosomal dominant hypophosphatemic rickets, von Hippel-Lindau disease, Denys-Drash syndrome, autosomal dominant severe congenital neutropenia, Costello syndrome, EEC syndrome, multiple cutaneous and mucosal venous malformations, diffuse nonepidermolytic palmoplantar keratoderma, Timothy syndrome, pheochromocytoma/paraganglioma syndrome 2, spondyloepimetaphyseal dysplasia with multiple dislocations, Brooke-Spiegler syndrome, macrocephaly-autism syndrome, pheochromocytoma/paraganglioma syndrome 3, Duane-radial ray syndrome, PCWH syndrome, heart-hand syndrome, Slovenian type, congenital stationary night blindness autosomal dominant 3, mandibulofacial dysostosis-microcephaly syndrome, multiple endocrine neoplasia type 4, juvenile cataract-microcornea-renal glucosuria syndrome, Crouzon syndrome-acanthosis nigricans syndrome, Birk-Barel syndrome, thrombophilia due to protein S deficiency, autosomal dominant, dyskeratosis congenita, autosomal dominant 2, dyskeratosis congenita, autosomal dominant 3, colorectal cancer, hereditary nonpolyposis, type 6, colorectal cancer, hereditary nonpolyposis, type 7, brain small vessel disease 2A, autosomal dominant, intellectual disability, autosomal dominant 14, intellectual disability, autosomal dominant 15, intellectual disability, autosomal dominant 16, hypopigmentation-punctate palmoplantar keratoderma syndrome, intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency, postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome, intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism, intellectual disability, autosomal dominant 29, intellectual disability, autosomal dominant 30, Houge-Janssens syndrome 2, severe achondroplasia-developmental delay-acanthosis nigricans syndrome, dyskeratosis congenita, autosomal dominant 6, epidermolysis bullosa simplex 6, generalized, with scarring and hair loss, autosomal dominant complex spastic paraplegia, early-onset autosomal dominant Alzheimer disease, muscular dystrophy, limb-girdle, autosomal dominant, Feingold syndrome, Carney complex, neuronopathy, distal hereditary motor, autosomal dominant, autosomal dominant coarctation of aorta, autosomal dominant spondylocostal dysostosis, autosomal dominant hypohidrotic ectodermal dysplasia, Cowden disease, autosomal dominant distal myopathy, autosomal dominant rhegmatogenous retinal detachment, palmoplantar keratoderma-spastic paralysis syndrome, Alagille syndrome due to a JAG1 point mutation, PTEN hamartoma tumor syndrome, gastric adenocarcinoma and proximal polyposis of the stomach, autosomal dominant proximal renal tubular acidosis, autosomal dominant spastic ataxia, Waardenburg syndrome, hereditary retinoblastoma, autosomal dominant hypocalcemia, Li-Fraumeni syndrome, Loeys-Dietz syndrome, hereditary hemorrhagic telangiectasia, hereditary inclusion body myopathy-joint contractures-ophthalmoplegia syndrome, microcephalic osteodysplastic dysplasia, Saul-Wilson type, autosomal dominant intermediate Charcot-Marie-Tooth disease, autosomal dominant cutis laxa, autosomal dominant nonsyndromic hearing loss, autosomal dominant optic atrophy, autosomal dominant Emery-Dreifuss muscular dystrophy, autosomal dominant cerebellar ataxia, autosomal dominant osteopetrosis, autosomal dominant epidermolytic ichthyosis, ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome, neurofibromatosis, autosomal dominant cataract, arthrogryposis, distal, type 2B2, arthrogryposis, distal, type 2B3, Charcot-Marie-Tooth disease, demyelinating, type 1G, Delpire-McNeill syndrome, LAMA5-related multisystemic syndrome, autosomal dominant oculocutaneous albinism, Charcot-Marie-tooth disease, axonal, type 2DD, Pilarowski-Bjornsson syndrome, intellectual disability, autosomal dominant, fatty acyl-CoA reductase 1 upregulation, GUCY2D-related dominant retinopathy, RPE65-related dominant retinopathy, autosomal dominant titinopathy, NOG-related symphalangism spectrum disorder, ALPL-related autosomal dominant hypophosphatasia, MYH10-related neurodevelopmental disorder with congenital anomalies, spastic paraplegia 30A, autosomal dominant, TMEM127-related tumor predisposition, MAX-related tumor predisposition, BMPR1A-related juvenile polyposis syndrome, RP1-related dominant retinopathy, Birt-Hogg-Dube syndrome, inclusion body myopathy and brain white matter abnormalities, KINSSHIP syndrome, autosomal dominant nebulin-related myopathy, IMPG1-related dominant retinopathy, PROM1-related dominant retinopathy, PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome, ALG8-related autosomal dominant polycystic kidney and/or liver disease, NOTCH1-related AOS spectrum disorder, FLNB-associated autosomal dominant filamin related bone disorder, familial antiphospholipid syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

209 retrieved; paginated sample, class counts are floors:

69 conflicting classifications of pathogenicity, 58 uncertain significance, 51 benign/likely benign, 19 benign, 6 likely pathogenic, 4 pathogenic, 2 pathogenic/likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
12435	NM_003282.4(TNNI2):c.521G>A (p.Arg174Gln)	TNNI2	Pathogenic	criteria provided, multiple submitters, no conflicts
12436	NM_003282.4(TNNI2):c.466C>T (p.Arg156Ter)	TNNI2	Pathogenic	criteria provided, multiple submitters, no conflicts
12437	NM_003282.4(TNNI2):c.524AGA[1] (p.Lys176del)	TNNI2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
12439	NM_003282.4(TNNI2):c.496GAG[1] (p.Glu167del)	TNNI2	Pathogenic	criteria provided, multiple submitters, no conflicts
212411	NM_003282.4(TNNI2):c.525G>T (p.Lys175Asn)	TNNI2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
694070	NM_003282.4(TNNI2):c.493A>T (p.Ile165Phe)	TNNI2	Pathogenic	no assertion criteria provided
1333897	NM_003282.4(TNNI2):c.520C>T (p.Arg174Trp)	TNNI2	Likely pathogenic	criteria provided, single submitter
2434182	NM_003282.4(TNNI2):c.503_505dup (p.Ser169Ter)	TNNI2	Likely pathogenic	criteria provided, single submitter
2506365	NM_003282.4(TNNI2):c.496G>T (p.Glu166Ter)	TNNI2	Likely pathogenic	criteria provided, single submitter
3064439	NM_003282.4(TNNI2):c.486G>T (p.Arg162Ser)	TNNI2	Likely pathogenic	criteria provided, single submitter
4293088	NM_003282.4(TNNI2):c.486G>C (p.Arg162Ser)	TNNI2	Likely pathogenic	criteria provided, single submitter
692080	NM_003289.4(TPM2):c.307C>A (p.Gln103Lys)	TPM2	Likely pathogenic	criteria provided, single submitter
14145	NM_002470.4(MYH3):c.700G>A (p.Ala234Thr)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
211555	NM_002470.4(MYH3):c.4910C>T (p.Ala1637Val)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
211557	NM_002470.4(MYH3):c.875C>G (p.Ser292Cys)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
258678	NM_002470.4(MYH3):c.3072C>G (p.Thr1024=)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321706	NM_002470.4(MYH3):c.*39G>A	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321707	NM_002470.4(MYH3):c.*31T>G	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321711	NM_002470.4(MYH3):c.5660A>G (p.Asp1887Gly)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321712	NM_002470.4(MYH3):c.5607G>T (p.Val1869=)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321713	NM_002470.4(MYH3):c.5562+11C>T	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321715	NM_002470.4(MYH3):c.5390G>A (p.Arg1797His)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321716	NM_002470.4(MYH3):c.5331C>T (p.Ser1777=)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321717	NM_002470.4(MYH3):c.5299G>A (p.Ala1767Thr)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321720	NM_002470.4(MYH3):c.5161-13C>T	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321725	NM_002470.4(MYH3):c.4323C>T (p.Ala1441=)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321726	NM_002470.4(MYH3):c.4238C>T (p.Ala1413Val)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321728	NM_002470.4(MYH3):c.4109C>T (p.Ala1370Val)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321729	NM_002470.4(MYH3):c.4082C>T (p.Ala1361Val)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
321731	NM_002470.4(MYH3):c.3731C>T (p.Ala1244Val)	MYH3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 26 · Orphanet: 16 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
MYH3	Strong	Autosomal dominant	distal arthrogryposis type 2B1	14
TNNI2	Strong	Autosomal dominant	distal arthrogryposis type 2B1	5
TNNT3	Strong	Autosomal dominant	distal arthrogryposis type 2B1	7

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TNNI2	Orphanet:1146	Distal arthrogryposis type 1
TNNI2	Orphanet:1147	Sheldon-Hall syndrome
TNNT3	Orphanet:1146	Distal arthrogryposis type 1
TNNT3	Orphanet:1147	Sheldon-Hall syndrome
MYH3	Orphanet:1146	Distal arthrogryposis type 1
MYH3	Orphanet:1147	Sheldon-Hall syndrome
MYH3	Orphanet:2053	Freeman-Sheldon syndrome
MYH3	Orphanet:2990	Autosomal recessive multiple pterygium syndrome
MYH3	Orphanet:3275	Spondylocarpotarsal synostosis
MYH3	Orphanet:65743	Autosomal dominant multiple pterygium syndrome
TPM2	Orphanet:1146	Distal arthrogryposis type 1
TPM2	Orphanet:1147	Sheldon-Hall syndrome
TPM2	Orphanet:171436	Typical nemaline myopathy
TPM2	Orphanet:171439	Childhood-onset nemaline myopathy
TPM2	Orphanet:171881	Cap myopathy
TPM2	Orphanet:2020	Congenital fiber-type disproportion myopathy

Cohort genes → proteins

4 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	4

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TNNI2	HGNC:11946	ENSG00000130598	P48788	Troponin I, fast skeletal muscle	gencc,clinvar
TNNT3	HGNC:11950	ENSG00000130595	P45378	Troponin T, fast skeletal muscle	gencc,clinvar
MYH3	HGNC:7573	ENSG00000109063	P11055	Myosin-3	gencc,clinvar
TPM2	HGNC:12011	ENSG00000198467	P07951	Tropomyosin beta chain	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TNNI2	Troponin I, fast skeletal muscle	Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
TNNT3	Troponin T, fast skeletal muscle	Troponin T is the tropomyosin-binding subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
MYH3	Myosin-3	Muscle contraction.
TPM2	Tropomyosin beta chain	Binds to actin filaments in muscle and non-muscle cells.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 3 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Scaffold/PPI	1	4.3×	0.404
Other/Unknown	3	1.3×	0.404

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TNNI2	Other/Unknown	no		Troponin, Troponin_sf, Troponin_I
TNNT3	Other/Unknown	no		Troponin, TNNT, Troponin_sf
MYH3	Scaffold/PPI	no		Myosin_head_motor_dom-like, Myosin_tail, SH3_Myosin
TPM2	Other/Unknown	no		Tropomyosin

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	4
unknown	0

Top tissues across cohort

Tissue	Cohort genes
gastrocnemius	2
hindlimb stylopod muscle	2
skeletal muscle tissue	2
left testis	1
right testis	1
testis	1
blood vessel layer	1
popliteal artery	1
saphenous vein	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TNNI2	134	broad	marker	hindlimb stylopod muscle, skeletal muscle tissue, gastrocnemius
TNNT3	135	broad	marker	hindlimb stylopod muscle, skeletal muscle tissue, gastrocnemius
MYH3	203	tissue_specific	yes	left testis, right testis, testis
TPM2	283	ubiquitous	marker	saphenous vein, popliteal artery, blood vessel layer

Protein interactions among cohort

Intra-cohort edges: 4.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MYH3	1,795
TNNI2	1,255
TNNT3	1,197
TPM2	357

Intra-cohort edges

A	B	Sources
MYH3	TNNI2	string_interaction
MYH3	TNNT3	string_interaction
MYH3	TPM2	biogrid_interaction
TNNI2	TNNT3	biogrid_interaction, string_interaction

Structural data

PDB: 1 · AlphaFold-only: 3 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TNNI2	P48788	2

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
TPM2	P07951	91.51
TNNT3	P45378	77.99
MYH3	P11055	74.35

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 3. Enrichment computed across 4 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Striated Muscle Contraction	4	308.6×	3e-10	TNNI2, TNNT3, MYH3, TPM2
Smooth Muscle Contraction	1	66.4×	0.022	TPM2
Muscle contraction	1	19.3×	0.051	MYH3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of ATP-dependent activity	2	4213.0×	3e-07	TNNT3, TPM2
skeletal muscle contraction	3	383.0×	3e-07	TNNI2, TNNT3, MYH3
sarcomere organization	2	191.5×	2e-04	TNNT3, MYH3
muscle contraction	2	104.0×	5e-04	MYH3, TPM2
positive regulation of calcium-dependent ATPase activity	1	4213.0×	7e-04	TNNT3
regulation of striated muscle contraction	1	526.6×	0.005	TNNT3
muscle filament sliding	1	263.3×	0.008	MYH3
actin filament-based movement	1	200.6×	0.009	MYH3
face morphogenesis	1	123.9×	0.012	MYH3
ATP metabolic process	1	117.0×	0.012	MYH3
embryonic limb morphogenesis	1	100.3×	0.012	MYH3
cardiac muscle contraction	1	100.3×	0.012	TNNI2
muscle organ development	1	41.7×	0.027	MYH3
actin filament organization	1	29.7×	0.036	TPM2
positive regulation of DNA-templated transcription	1	7.0×	0.136	TNNI2

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 4

Druggability breadth: 2 of 4 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TNNI2	0	0
TNNT3	0	0
MYH3	0	0
TPM2	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	4	TNNI2, TNNT3, MYH3, TPM2

Undrugged target profiles

4 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
TNNI2	0	—
TNNT3	0	—
MYH3	0	—
TPM2	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.